Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Adalimumab in Plaque Psoriasis (IMMvent)
NCT02694523Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in plaque psoriasis (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index at 16 weeks, Percentage of Participants Achieving Static Physician Global Assessment Score of Clear or Almost Clear at 16 weeks and 1 more. Started Mar 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02694523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694523.